Comparing Innovation Spending: Pfizer Inc. and Corcept Therapeutics Incorporated

Pfizer vs. Corcept: A Decade of R&D Investment

__timestampCorcept Therapeutics IncorporatedPfizer Inc.
Wednesday, January 1, 2014183720008393000000
Thursday, January 1, 2015154190007690000000
Friday, January 1, 2016238440007872000000
Sunday, January 1, 2017403760007657000000
Monday, January 1, 2018752470008006000000
Tuesday, January 1, 2019890170008650000000
Wednesday, January 1, 20201147640009405000000
Friday, January 1, 202111386400013829000000
Saturday, January 1, 202213099100011428000000
Sunday, January 1, 202318435300010679000000
Monday, January 1, 202410930000000
Loading chart...

In pursuit of knowledge

A Tale of Two Innovators: Pfizer Inc. vs. Corcept Therapeutics

In the ever-evolving landscape of pharmaceutical innovation, research and development (R&D) spending is a key indicator of a company's commitment to future growth. From 2014 to 2023, Pfizer Inc. and Corcept Therapeutics Incorporated have demonstrated contrasting approaches to R&D investment. Pfizer, a global giant, consistently allocated substantial resources, peaking at approximately $13.8 billion in 2021. This represents a 79% increase from its 2014 spending. In contrast, Corcept Therapeutics, a smaller player, showed a remarkable growth trajectory, with R&D expenses surging by over 900% during the same period, reaching around $184 million in 2023. This stark difference highlights the diverse strategies within the pharmaceutical sector, where both large-scale and niche companies strive to innovate and lead in their respective fields.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025